Hooper, Perry B.Farberg, Aaron S.Fitzgerald, Alison L.Siegel, Jennifer J.Rackley, Briana B.Prasai, AneshKurley, Sarah J.Goldberg, Matthew S.Litchman, Graham H.2024-06-212024-06-212022-09Hooper, P. B., Farberg, A. S., Fitzgerald, A. L., Siegel, J. J., Rackley, B. B., Prasai, A., Kurley, S. J., Goldberg, M. S., & Litchman, G. H. (2022). Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Cancer Investigation, 40(10), 911–922. https://doi.org/10.1080/07357907.2022.2116454https://hdl.handle.net/1805/41764Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.en-USAttribution-NonCommercial-NoDerivatives 4.0 Internationalcutaneous squamous cell carcinoma (cSCC)40-gene expression profile (40-GEP)metastasisprognosticrisk-stratificationArticle